Revolutionizing Diagnosis and Treatment with Adaptive Biotechnologies’ Immune Medicine Platform

Adaptive Biotechnologies Announces Business Update Conference Call and Webcast Scheduled for April 2, 2024

Adaptive Biotechnologies Corporation, a biotechnology company listed on the Nasdaq under the ticker symbol ADPT, is focused on utilizing the biology of the adaptive immune system to revolutionize disease diagnosis and treatment. The company believes that this powerful tool has not been fully utilized due to the challenges of decoding it. With its immune medicine platform, Adaptive Biotechnologies is able to decode the genetics of the adaptive immune system with scale, precision, and speed.

The company collaborates with biopharmaceutical companies, informs drug development, and develops clinical diagnostics in two main areas: Minimal Residual Disease (MRD) and Immune Medicine. Their products and pipeline aid in diagnosing, monitoring, and treating diseases such as cancer, autoimmune disorders, and infectious diseases with the goal of developing personalized immune-driven clinical products for each patient.

On Tuesday, April 2nd 2024 at 1:30 p.m Pacific Time / 4:30 p.m Eastern Time Adaptive Biotechnologies will be hosting a business update conference call and webcast after the market closes. The live audio of the webcast will be available on the “Investors” section of their website at www.adaptivebiotech.com. The webcast will also be archived for replay within 24 hours after the event.

For investors inquiries can contact Karina Calzadilla Vice President of Investor Relations at investors@adaptivebiotech.com . For media inquiries contact Erica Jones Associate Director of Corporate Communications at media@adaptivebiotech

Leave a Reply